Change Theme
CNBC TV18
Tue, Aug 27, 2024
Zydus Lifesciences secures USFDA approval for Amantadine extended-release capsules
Shares of Zydus Lifesciences Ltd ended at ₹1,113.85, up by ₹5.40, or 0.49% on the BSE.